Phares Pharmaceutical Research, N.v.

Phares Pharmaceutical Research N.v. Et Al.

Phares Technology Bv

Phares Drug Delivery Ag

Mathew Louis Steven Leigh

Peter Van Hoogevest

Steve Leigh

Steven Leigh

Jacques Quinton

Daniel Streich

Caroline Mary Thompson

Henricus Tiemessen

There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.

Dissolution composition for examining drug solubility

The present disclosure describes a method for the continuous dissolution of e.g. crystalline astaxanthin or canthaxanthin suspension in oil, by applying heat for a predetermined period using an in-line or optionally batch wise-process, followed by cooling the heated solution with an oil phase or heat exchanger. The resulting oil solution may be used as such or added directly to feed components which are turned into feed compositions by extrusion, compaction or granulation. Alternatively the oil solution is spray coated or directly loaded to extruded or compacted pellets and granulates. The disclosure avoids using formulated carotenoids prepared by known multi-step production methods requiring solvents, solvent removal, cooling and emulsification with an aqueous phase or precipitation and recovery steps. Thus the present invention is a more economical, efficient and environmentally friendly method to add nutrients and colorants to feed compositions instead of using colloid dispersed particulate hydrocolloid compositions.

Direct dissolution

Mixtures of specific crystal forms of astaxanthin and the individual crystal forms designated crystal Form I and II and disclosed together with methods for preparing said crystal Forms. Methods for preparing nutritional dosage forms including the disclosed astaxanthin crystal forms for the life science industry are also disclosed.

Crystal forms of astaxanthin

A composition in the form of a dry powder and which comprises: a) at least one membrane lipid, and b) at least one biologically active compound comprising a xanthine and/or a carboxylic acid, and which forms structured lipid assemblies when dispersed/dissolved in an aqueous medium. A method of preparing such a composition is also provided, together with a dispersion of structured lipid assemblies suspended in a solution of at least one biologically active compound and a method of preparing the same. The compositions and dispersions are suitable for use in creams and lotions for skin care.

Membrane lipid compositions

A substantially homogeneous composition for human administration comprises a biologically active lipophilic compound dissolved in or associated with at least one micelle-forming lipid. For example, cyclosporin A is dissolved or dispersed in the mixture of PC and MAPC. The composition may be made by dissolving the lipid material in ethanol, adding the lipophilic compound to the ethanol and removing the ethanol, after which the composition may be formulated for human oral administration.

Growing community of inventors

Muttenz, Switzerland

Mathew Louis Steven Leigh